A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|HR+/HER2- Breast Cancer
Interventions: DRUG: BPI-1178|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: BPI-1178
Sponsor: Beta Pharma (Suzhou) Co., Ltd.